Chemical space
Unknown small molecule drugs
Intelligent end-to-end processes

DeepCure is harnessing the power of AI-driven drug discovery to accelerate the development of novel, first-in-class precision therapeutics in areas of unmet medical need. 

Our experienced scientists and engineers optimize all phases of drug-discovery, including early hit identification, hit-to-lead, lead optimization, patent strategy, and preparation for IND filing, yielding shorter timelines to develop the highest-quality drug candidates.

We are using AI-driven drug discovery to ensure better molecules and faster cures. Our mission is to discover, develop and deliver to patients novel, small molecule drugs that were previously undruggable or undiscovered until our technology came along.

Binding Modeling

Hypothesis Generation


One of the most critical components of our drug discovery pipeline, and one that differentiates us from the rest of the AI drug discovery companies, is our ability to create causal, data-driven, human-interpretable hypotheses for a wide range of targets.


Discovering novel binding modes is the first step towards finding novel therapies

For most therapeutic targets of interest today, there is either no data, limited data, or biased data. For that reason, we start by generating a hypothesis from scratch, using only information about the approximate binding region that gives rise to the desired phenotype. Using PocketExpander™, our proprietary pocket mapping tool that leverages AI/ML as well as comp Chem methods, we are able to identify potential relevant binding modes. The output is then used as an initial binding hypothesis that is fed into MolGen. The data obtained from synthesis and physical testing of molecules predicted by MolGen are then used to refine our hypothesis using causal analysis.

Structure Preparation

We fundamentally believe that discovering novel small molecules requires an understanding of the physics and chemistry of binding and therefore, requires 3D structural models of the protein-ligand complexes. More common methods that focus on the ligand chemical graph through SMILES strings or pharmacophores cannot sufficiently model the information relevant for binding. 

To prepare a structure, we use a combination of publicly available crystal structures, internal structures, and predicted structures and run them through our proprietary structure preparation protocols. Using our Magneto platform, we automatically analyze the structures’ quality, align reference frames, build missing pieces, and then manually review them.

Causal Analysis

Machine Learning methods usually used for drug discovery are inherently focused on correlations. Since data sets around binding are often very small and highly biased, these methods will often get trapped by the bias and be unable to discover truly novel chemical matter. Our Causal ML methods for Hypothesis Generation analyzes the 3-dimensional structure from a physics-based perspective and uses causal analysis to find just the interactions relevant for binding in an unbiased way; thereby, unlocking new indications and safety profiles.

Medicinal chemists engage in a conversation with explainable models

On top of the strength of the causal hypothesis, it is designed to be human-interpretable, allowing scientists to make updates or experiment further in novel binding/selectivity modes. Causal features can then be shown as heatmaps in 3D (or mapped to 2D) and can be reviewed by medicinal and computational chemists to identify irregularities or gaps and customize them to explore additional interesting regions or interactions. This allows for a feedback cycle that ensures we don’t blindly follow the ML algorithm or a chemist’s intuition.

TCP-Aware Drug Design


Our patent-pending molecular generation tool, MolGen™, is used to design novel, diverse compounds that are readily synthesizable and fit the desired TCP for a given drug program.

The molecular generation process leverages state of the art deep reinforcement learning (RL) to construct synthesizable molecules that efficiently capture all causal interactions for binding and selectivity while maintaining the desired ADME-tox profile. 

MolGen™ utilizes hundreds of workers, choreographed in a unified pipeline (leveraging distributed training, hyperparameter optimization, GPU instances, and more), to improve the output quality of molecules as quickly as possible.

Prospective Evaluation of Accuracy

Multiparameter Optimization (MPO)

In parallel to our binding and selectivity hypothesis generation models, we have trained several state-of-the-art models (DeepPropR™), leveraging both public and proprietary data sources, to predict important pharmacological properties (ADME-Tox). Our DeepPropR™ models are frequently validated experimentally on molecules we synthesize to ensure an accurate measurement of the models’ performance and generalizability.

The figure (left) depicts the accuracy of our ten most used DeepPropR™ models from a prospective evaluation. Most of these accuracy data include results from at least 200 compounds that were not part of the training set but were generated from our internal pipeline and subsequently evaluated via physical testing. DeepPropR™models are also available for on-the-fly inference at scale using our custom-built Molecular Property Service (learn more in our relevant blog post, here).

Robotic Synthesis & Automated Physical Testing

Molecular Foundry

A large number of potentially outstanding compounds designed for a given drug discovery program are tossed as a result of decisions that led to them either not being synthesized or only partially characterized due to long timelines and high costs of manual synthesis and assays. 

DeepCure’s Automated Molecular Foundry seeks to reduce design-build-test-learn cycle times and cost without limiting novelty and diversity of compounds via a fully integrated platform that includes robotic automation software, robotic synthesis, and assay automation.

Using AI and cutting-edge automation, we can reduce cost and cut cycle times. The chemistry is based on robotic synthesizers, MS-triggered purification systems, and liquid-handling systems, while automated screening and in-vitro testing generates up to a 100,000 datapoints per month.

This AI-to-Bench integrated workflow will ensure that novel in-silico target discoveries are immediately and directly validated in-vitro and fed back into the AI pipeline to optimize for success. This streamlined process shortens cycle times, increases efficiency and reduces costs.

Advanced Computational Methods to Accelerate Cures

With automated synthesis technologies, we can identify the right compounds and synthetic routes, at a much quicker turnaround time. On the biology front, our internal screening capabilities will ensure that DeepCure has access to the ideal data for our machine learning models.

Molecular Foundry

Manual synthesis dramatically stifles innovation in drug discovery for many reasons, including (i) substantial time costs, (ii) high FTE costs, (iii) low synthesis success rates (20-34%), and (iv) a bias towards known reactions.

At DeepCure, we are fixing these problems to unlock the vast chemical space that AI drug design tools want to explore, but don’t, because manually synthesizing such compounds would not be practicable.

Automated Robotic Custom Synthesis

Manual synthesis dramatically stifles innovation in drug discovery for many reasons, including (i) substantial time costs, (ii) high FTE costs, (iii) low synthesis success rates (20-34%), and (iv) a bias towards known reactions. 


At DeepCure, we are fixing these problems to unlock the chemical space that AI drug design tools want to explore but can’t because it is not practicably available to most chemists.














made possible with automated analytical evaluation, purification, evaporation, etc.

made practicable with automated reaction development

made feasible with miniaturization & quick turnaround (2-10 days)

Notes: 1 4+ by Q2 2024. 2 Planned to reach by end of 2024.


Our molecular generation tool, MolGen™, designs novel, diverse compounds. Using state-of-the-art deep reinforcement learning (RL), MolGen™ constructs synthesizable compounds with features that capture the important molecular interactions for binding and selectivity, as well as deliver the desired ADME-tox profile of the target candidate profile (TCP).

Output of PocketExpander™

MolGen™ – building & iterating compounds

Novel, potent, & selective compound

Hypothesis Generation

Unlike other AI drug discovery companies, DeepCure does not use AI to simply match a library of compounds to a known pocket. Instead, we use our patent-pending AI methods to create causal, data-driven, human-interpretable hypotheses for binding to a given protein target. This enables us to go beyond known binding sites and ligands.


Our hypothesis generation starts with a rigorous analysis of available structural information. Beyond the standard steps involved in structure preparation, our proprietary protocols also include methods for repairing structures (e.g. building missing loops) and generating more robust structures leveraging molecular dynamics (MD).


For most therapeutic targets, there is no data, limited data, or biased data. PocketExpander™ allows us to generate novel hypotheses by leveraging AI/ML and computational chemistry methods to map the protein surface and identify novel binding modes (shown as colored dots). The outputs serve as the blueprints for our molecular generation tool, i.e. MolGen™.

Causal Analysis

ML methods for drug discovery typically focus on correlations, which lead to biases for the types of compounds that have previously failed in discovery. In contrast, DeepCure uses a causal ML approach to find binding interactions without the biases for fruitless binding modes to design truly novel compounds.

Medicinal chemists engage in a conversation with explainable models

DeepCure’s platform is designed to be human-interpretable. By seeing how molecules are predicted to interact with the protein, scientists can make rational design changes to the molecule and explore interesting molecular interactions – ensuring we don’t blindly follow the ML algorithm or chemists’ intuition.